Acute promyelocytic leukemia Primary Prevention

Revision as of 13:04, 25 January 2019 by Sogand (talk | contribs) (→‎Overview)
Jump to navigation Jump to search

Acute promyelocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute promyelocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary PreventionSurgery

Secondary PreventionSurgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute promyelocytic leukemia Primary Prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute promyelocytic leukemia Primary Prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute promyelocytic leukemia Primary Prevention

CDC on Acute promyelocytic leukemia Primary Prevention

Acute promyelocytic leukemia Primary Prevention in the news

Blogs on Acute promyelocytic leukemia Primary Prevention

Directions to Hospitals Treating Acute promyelocytic leukemia

Risk calculators and risk factors for Acute promyelocytic leukemia Primary Prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

There are no established measures for the primary prevention of acute promyelocytic leukemia

There are no available vaccines against acute promyelocytic leukemia .

Effective measures for the primary prevention of acute promyelocytic leukemia in fatal is

Primary Prevention

There are no established measures for the primary prevention of acute promyelocytic leukemia .

There are no available vaccines against acute promyelocytic leukemia .

Effective measures for the primary prevention of acute promyelocytic leukemia include:

  • White blood cell (WBC) count more than 10,000,000,000
  • Age> 60

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:

  • [Strategy 1]
  • [Strategy 2]
  • [Strategy 3]

References

Template:WH Template:WS